MedWatch

As raw material and energy prices rise, so do Coloplast's costs

In Tuesday’s Q1 financial results, medtech company Coloplast’s top and bottom lines reported growth, but increasing energy expenses and wage inflation in Hungary have meant that production costs have also gone up during the first quarter.

Anders Lonning-Skovgaard, EVP and CFO at Coloplast | Photo: Coloplast / PR

It is not only Coloplast’s top and bottom lines that have taken leaps in the first quarter of the skewed financial year 2021/2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs